home All News open_in_new Full Article
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
today 8 d. ago attach_file Other
attach_file
Events
attach_file
Other
attach_file
Economics
attach_file
Other
attach_file
Politics
attach_file
Other
attach_file
Politics
attach_file
Economics
attach_file
Economics
attach_file
Economics
attach_file
Other
attach_file
Transport
ID: 1544051049